Background: Older adults living in long-term care facilities (LTCFs) are at increased risk for
severe outcomes from COVID-19 and were identified as a priority group in COVID-19 …

Clinical and biological assessment of the COVID-19 vaccine efficacy in the frail population is
of crucial importance. The study focuses on measuring the levels of anti-SARS-CoV-2 IgG …

The elderly residing in long-term care facilities (LTCFs) are a group at high risk for COVID-
19. Hence, monitoring of the vaccine-based immunity has a pivotal role in identifying …

Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

Background. Several Canadian provinces are extending the interval between COVID-19
vaccine doses to increase population vaccine coverage more rapidly. However …

Although the safety and efficacy of COVID-19 vaccines in older people are critical to their
success, little is known about their immunogenicity among elderly residents of long-term …

Despite the high efficacy of the BNT162b2 vaccine in the general population, data on its
immunogenicity among frail elderly individuals are limited. Recently, levels of anti-SARS …

Background There is incomplete information regarding evolution of antibody titers against
SARS‐CoV‐2 after a two‐dose strategy vaccination with BNT162b2 in older adults in long …

Abstract Background/Objectives The safety and immunogenicity of the BNT162b2
coronavirus disease 2019 (COVID‐19) vaccine in older adults with different frailty and …

Introduction BNT162b2 (BioNTech and Pfizer) is a nucleoside-modified mRNA vaccine that
provides protection against SARS-CoV-2 infection and is generally well tolerated. However …